logo-loader
viewReNeuron Group PLC

ReNeuron Group's phase IIb stroke trial kicks off with first patient treated

ReNeuron Group PLC’s (LON:RENE) Michael Hunt tells Proactive London's Andrew Scott the first person has now been treated in the US phase IIb clinical study of their CTX stem cell therapy candidate for stroke disability.

The mid-stage trial, called PISCES III, will see 110 patients with stable post-stroke disability given either the CTX therapy or a placebo.

ReNeuron wants to show that the patients on its treatment see a “clinically significant” improvement on the Modified Rankin Scale – a measure of disability and dependence – after six months.

Top-line results are due early next year.

Quick facts: ReNeuron Group PLC

Price: 151.5 GBX

LSE:RENE
Market: LSE
Market Cap: £48.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron's retinal treatment 'appears to have sustained long-term beneficial...

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott soon after the firm announced that its cell therapy for a degenerative eye disease held onto sight improvements for as long as a year after treatment. The 12-month data reveal that people receiving...

14 hours, 42 minutes ago

2 min read